Cell Medica is committed to improving patients’ lives through the significant therapeutic potential of cellular immunotherapy. Our approach is to apply innovative technologies with the aim of improving the treatment of cancer. We are seeking a motivated Senior Viral/Non-Viral Vector Scientist to join our team in Schlieren, Switzerland.
To lead the development of viral and non-viral vectors to engineer T and NKT cells to treat human cancers. The candidate will interface between research and product development and will be responsible not just for the engineering of the vectors but also for providing key guidance for process development and GMP manufacturing of the vectors moving into the clinic. The successful candidate will have in-depth expertise of retrovirus, lentivirus and AAV viral vector design as well as non-viral vector design and their application for cellular immunotherapies. The purpose of this position is to provide hands-on experience from vector selection, construction, and production to the development and implementation of innovative analytical technologies for vector characterization. This position is full time and based in Schlieren, Switzerland.
Responsible to: Chief Scientific Officer
Education and Experience
• Team and service oriented
• Highly organized
• Dependable and meets commitments
• Quality and detail oriented with high standards
• Strong planning and organizational skills, verbal, written
• Well-developed communication skills, good at listening and sharing information with others
• Ability to act on own initiative within inter-related team communication
• Excellen t verbal and written English language is essential
Applicants should submit CV/Resume and cover letter here: https://cellmedica.peoplehr.net/Pages/JobBoard/Opening.aspx?v=edb7232e-ebae-41d1-b80a-815ab53e5f29#
The job posting may be closed early if we receive a high volume of CVs so please apply at your earliest convenience.
This job description is subject to change at any time.
About Cell Medica
Cell Medica is committed to improving patients’ lives through the significant therapeutic potential of cellular immunotherapy. Our approach is to apply innovative technologies with the aim of improving the treatment of cancer.
We have developed a business platform that has positioned Cell Medica as a leader in the manufacture and commercialization of cellular products. We collaborate with leading academic institutions to turn early stage innovations into medicinal products.
Our highly dedicated team embrace the challenges that the field of cellular therapies presents. With patient benefits at the forefront of our activities, we overcome the considerable challenges through collaboration and the will to succeed.
The personal data you provide as part of the recruitment process will only be held and processed for the purpose of the selection process and in connection with any subsequent employment or placement.
Unsuccessful applicant data will be held within the recruitment system for a period of one year before being deleted.
If you wish Cell Medica to update or erase your personal information, requests should be made to in writing to email@example.com
Please be aware that Cell Medica uses a third party supplier to hold the information you submit. The third party company complies with General Data Protection Regulation and Cell Medica’s security policy and therefore will not share your data with anyone other than Cell Medica. In the event of your application resulting in an offer and your acceptance of a position at Cell Medica, your personal information will continue to be held by the same third party supplier and form part of Cell Medica’s employee database. Your application paperwork and personal details will be transferred to Cell Medica’s electronic personnel files. Cell Medica will process your data for the purposes of administrating your employment. Your application paperwork and personal information will be retained for the duration of your employment and for a period of time following this. You have the right to request a copy of the data held.
Cell Medica AG
Ms Eleanor Jones